You are here

Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients

Last updated on December 6, 2018

FOR MORE INFORMATION
Study Location
CHU de la Timone
Marseille, Cedex 5, 13335 France
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Complete Remission in Renal Cell Carcinoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-99 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients with metastatic renal cell carcinoma, histopathologically confirmed

- Treated with sunitinib according to Smpc

- For cases: Achieving a CR (local assessment according to RECIST V1.0 criteria) with
Sunitinib in prior 6 months alone OR in combination with local treatment (surgery,
radiation therapy, ablative techniques: cryotherapy, RFA)

- For controls: Life expectancy > 3 months No prior Sunitinib treatment

- Patient >18 years

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Sunitinib administered in a non-approved label

- For cases: CR occurring without sunitinib treatment

- For controls: Prior systemic treatment

NCT01934452
Pfizer
Recruiting
Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Squamous Cell Carcinoma of the Head and Neck (SCCHN)
NCT02499120
All Genders
18+
Years
Multiple Sites
Pancreatic Cancer, Non-Small Cell Lung Cancer, Cancer
NCT03637491
All Genders
18+
Years
Multiple Sites
Solid Tumors, Ewing Sarcoma, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma
NCT03709680
All Genders
Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients
Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients

This prospective study will investigate the characteristics of mRCC patients at time of CR in comparison with mRCC patients non on CR treated with Sunitinib, in order to provide some answers/ refection leads to the following questions :

Can we identify blood specificity at time of CR vs non on CR? Shall we distinguish CR with sunitinib alone from combined CR (sunitinib with local treatment), while in clinical report these 2 cohorts present similar time to recurrence (ALBIGES, ASCO 2010)? Can we identify potential predictive serum biomarkers of recurrence? (With the aim of isolating blood biomarker that can help on treatment discontinuation decision?)

The main objective of the study is to describe the characteristics of mRCC patients on CR with Sunitinib (Cases) and compare them to the characteristics of mRCC patients non on CR (controls) in order to identify factors associated with the occurrence of complete remission.

The results obtained on the sample must be representative of the population targeted by the study. The most appropriate method to obtain a representative sample is probability sampling.

A sample size of N = 40 (cases) and N = 80 (Controls) will provide a power of 80% in the detection of a frequency difference between cases and controls corresponding to an OR of 0.24 for a parameter frequency 10% in control arm and an OR of 0.30 for a parameter frequency of around 30% in control arm. The significance level was set at bilateral 5%.

The data will be analyzed using SAS software (version 9.1 - SAS Institute, North Carolina, United States).

Observational
Observational Model: Case-Control
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
whole blood and serum
Probability Sample
complete remission in mRCC patients treated with sunitinib versus non complete remission in mRCC patients treated with sunitinib
Complete Remission in Renal Cell Carcinoma
  • Drug: sunitinib
    50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months
    Other Name: Cases
  • Drug: sunitinib
    50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months
    Other Name: Controls
  • Complete Remission
    Complete remission arm in mRCC patients treated with sunitinib.
    Intervention: Drug: sunitinib
  • Non Complete Remission
    Non complete remission arm in mRCC patients treated with sunitinib.
    Intervention: Drug: sunitinib
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
120
April 15, 2020
April 15, 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with metastatic renal cell carcinoma, histopathologically confirmed
  • Treated with sunitinib according to Smpc
  • For cases: Achieving a CR (local assessment according to RECIST V1.0 criteria) with Sunitinib in prior 6 months alone OR in combination with local treatment (surgery, radiation therapy, ablative techniques: cryotherapy, RFA)
  • For controls: Life expectancy > 3 months No prior Sunitinib treatment
  • Patient >18 years

Exclusion Criteria:

  • Sunitinib administered in a non-approved label
  • For cases: CR occurring without sunitinib treatment
  • For controls: Prior systemic treatment
Sexes Eligible for Study: All
18 Years to 99 Years   (Adult, Senior)
No

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
France
 
 
NCT01934452
NRA6180080
A6181209 ( Other Identifier: Alias Study Number )
Yes
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2017

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now